BIOA-B.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 geg. 2024 @ 18:29):

BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden...

Stats
Dzisiejszy wolumen	83 310.00
Średni wolumen	150 761
Kapitalizacja rynkowa	17.68B
EPS	SEK0 ( 2024-02-14 )
Następna data zysków	( SEK-0.750 ) 2024-05-17
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	77.45
ATR14	SEK0.345 (0.17%)

Wolumen Korelacja

Długi: 0.21 (neutral)

Krótki: -0.61 (weak negative)

Signal:(46.657) Neutral

BioArctic AB (publ) Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BioArctic AB (publ) Korelacja - Waluta/Towar

-0.10
( neutral )

-0.19
( neutral )

0.70
( moderate )

-0.01
( neutral )

0.74
( moderate )

BioArctic AB (publ) Finanse

Annual	2023
Przychody:	SEK616.00M
Zysk brutto:	SEK346.32M (56.22 %)
EPS:	SEK2.60

FY	2023
Przychody:	SEK616.00M
Zysk brutto:	SEK346.32M (56.22 %)
EPS:	SEK2.60

FY	2022
Przychody:	SEK228.29M
Zysk brutto:	SEK153.97M (67.44 %)
EPS:	SEK-0.130

FY	2021
Przychody:	SEK23.15M
Zysk brutto:	SEK-31.92M (-137.91 %)
EPS:	SEK-1.360

Financial Reports:

No articles found.

BioArctic AB (publ)

BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.